Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RARE · Real-Time Price · USD
46.74
+0.34 (0.73%)
Nov 21, 2024, 12:04 PM EST - Market open
Ultragenyx Pharmaceutical Revenue
Ultragenyx Pharmaceutical had revenue of $139.49M in the quarter ending September 30, 2024, with 42.27% growth. This brings the company's revenue in the last twelve months to $522.75M, up 27.44% year-over-year. In the year 2023, Ultragenyx Pharmaceutical had annual revenue of $434.25M with 19.52% growth.
Revenue (ttm)
$522.75M
Revenue Growth
+27.44%
P/S Ratio
7.71
Revenue / Employee
$409,675
Employees
1,276
Market Cap
4.31B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 434.25M | 70.92M | 19.52% |
Dec 31, 2022 | 363.33M | 11.92M | 3.39% |
Dec 31, 2021 | 351.41M | 80.38M | 29.66% |
Dec 31, 2020 | 271.03M | 167.32M | 161.32% |
Dec 31, 2019 | 103.71M | 52.22M | 101.41% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Oscar Health | 8.22B |
ICU Medical | 2.34B |
Integer Holdings | 1.71B |
Alkermes | 1.51B |
Haemonetics | 1.36B |
Prestige Consumer Healthcare | 1.11B |
Axsome Therapeutics | 338.46M |
TG Therapeutics | 264.79M |
RARE News
- 19 hours ago - Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 9 days ago - Ultragenyx: Ready For More Growth After Q3 Earnings Beat - Seeking Alpha
- 12 days ago - Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST's 17th Annual Global Science Summit - GlobeNewsWire
- 15 days ago - Ultragenyx Pharmaceutical Inc. (RARE) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 15 days ago - Ultragenyx Reports Third Quarter 2024 Financial Results and Corporate Update - GlobeNewsWire
- 6 weeks ago - Ultragenyx Provides Update on Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease - GlobeNewsWire
- 2 months ago - Ultragenyx Announces Upcoming Setrusumab (UX143) Presentations at the ASBMR 2024 Annual Meeting - GlobeNewsWire
- 2 months ago - Ultragenyx to Participate in Investor Conferences in September - GlobeNewsWire